Climate change is a major threat to public health. And while everyone’s health is at risk, some populations are at greater risk. This includes low-income communities, communities of color, and people with chronic diseases like asthma. But people living with asthma can take action to reduce the risks and impacts of climate change.

On May 25, 2023, the Asthma and Allergy Foundation of America (AAFA) hosted a webinar on climate change and asthma. We talked about:

• Asthma and health disparities
• The impacts of climate change
• Common climate change myths and misconceptions
• Your asthma and climate change
• How you can take action against climate change today

Watch on YouTube

Related Resources

• Asthma Capitals™ report
• Allergy Capitals™ report
• Asthma Disparities in America report
• asthma & allergy friendly® Certification Program
• Asthma Facts
• What Are Asthma Triggers?
• How to Correctly Use Your Asthma Devices
• Air quality reports from AirNOW.gov
  
  

On this final Friday of National Asthma and Allergy Awareness Month, the Asthma and Allergy Foundation of America (AAFA) and Kids with Food Allergies (KFA), our food allergy division, are holding a Remembrance Day in honor of family members and loved ones who’ve died from asthma or anaphylaxis. We also take time to remember others who have needlessly been lost to preventable deaths.

On average, more than 3,700 people in the U.S. die from asthma each year.¹ A few hundred more die each year because of severe allergic reactions, called anaphylaxis [anna-fih-LACK-sis].² Most of these deaths were preventable. We believe one life lost to asthma or anaphylaxis is one too many.

On this day, we reflect on our mission to save lives and reduce the burden of these diseases on individuals and families.

We dedicate May 26 as a time to celebrate and honor lives lost and to continue to make a difference in memory of the people who live in our hearts forever.

Watch on YouTube

Ways You Can Honor People Lost to Asthma and Anaphylaxis

At AAFA and KFA, we are blowing bubbles to remember lives lost. We encourage you to join us. Here are some ways you can show your respects:

• Blow bubbles in memoriam: Share a photo on social media blowing bubbles or of a loved one using the hashtag #AsthmaAwareness, #AllergyAwareness, or #FoodAllergyAwareness and tag AAFA or KFA.
• Write a poem, draw a picture, take a photograph of something your loved one would find beautiful, or sing or write a song using the hashtag #AsthmaAwareness, #AllergyAwareness, or #FoodAllergyAwareness and tag AAFA or KFA.
• Share a memory of a loved one in the comments below, or join our AAFA or KFA communities and share your memories on our forums.
• Send a card in the mail, make a phone call, or drop a text to friends or family to share support and fond memories.
• Make a donation to support AAFA’s work in memory of a loved one.
  
  

What AAFA and KFA Are Doing to Reduce Asthma and Anaphylaxis Deaths

AAFA and KFA work to fulfill our mission through several programs and initiatives. Your support makes these programs possible. Here are some of the ways we are working to reduce deaths from asthma and anaphylaxis:

• Advocacy – Support for public policies that will benefit people with asthma and allergies
• Community Health Interventions to Advance Self-Management of Asthma (CHI-ASMA) – A program backed by a grant from the Centers for Disease Control and Prevention (CDC) to help people with asthma improve asthma control
• Educational programs and resources – Evidence-based programs on asthma and food allergies for patients, caregivers, and health care professionals, including online courses and downloadable handouts
• Health Equity Advancement and Leadership (HEAL) program – Addresses health disparities in communities that bear the heaviest burden of asthma
• National Institutes of Health (NIH) partnership – Promotes clinical research that aims to better understand food allergies and related conditions, and find ways to better diagnose and treat people with food allergies
• Online Communities for Patients and Caregivers – Forums where you can connect with others who manage asthma, allergies, allergic skin conditions, and food allergies for information and moral support
• Support for Military Members and Families Managing Asthma on AAFA’s Online Community – a private group that provides peer support for military members, veterans, and their families to manage asthma

References
1. National Center for Health Statistics. National Vital Statistics System: Underlying Cause of Death 2018-2021. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. https://wonder.cdc.gov/ucd-icd10-expanded.html
2. Jerschow, E., Lin, R. Y., Scaperotti, M. M., & McGinn, A. P. (2014). Fatal anaphylaxis in the United States 1999-2010: temporal patterns and demographic associations. The Journal of Allergy and Clinical Immunology, 134(6), 1318-1328.e7. https://doi.org/10.1016/j.jaci.2014.08.018

It’s common to see the terms “hypoallergenic” or “allergy free” on many products and services. These are terms many consumers have become familiar with. Many people even seek out products and services with these labels. They can give the impression anything with these labels are healthier and less likely to trigger asthma and allergy symptoms.

But you may be surprised to find there are no regulations on how a product can be labeled “hypoallergenic” or “allergy free.” The Food and Drug Administration (FDA) says, “There are no Federal standards or definitions that govern the use of the term ‘hypoallergenic.’ The term means whatever a particular company wants it to mean.”

In some cases, the word is just marketing. But people with asthma and allergies need claims to be backed by science. Their health depends on it.

Standards That Matter

This is why the asthma & allergy friendly® Certification Program is based on science. The Certification Program was created to address the needs of the 100 million people in the U.S. with asthma and/or allergies. It is a unique collaboration between the Asthma and Allergy Foundation of America (AAFA) and Allergy Standards Limits (ASL). Products and services are tested to meet strict scientific standards developed by AAFA and ASL. Only products that meet these standards earn the asthma & allergy friendly® Certification mark. This helps consumers with asthma and allergies find and choose products that reduce indoor asthma and allergy triggers and contribute to healthier indoor environments.

Reducing exposure to triggers and allergens is critical to controlling asthma and allergy symptoms. And because of that, we need products and services backed by science, not marketing.

After Leo “Nacho” Adams was hospitalized at the age of 6 for a severe asthma attack –during which he also had a heart attack – his family was told he would never be able to play a sport. Instead, it was suggested that he consider the chess team. Outdoor activities were deemed particularly dangerous for Nacho as the conditions and activity might trigger his symptoms.

That frightening event and concerning diagnosis happened 11 years ago.

Today, Nacho is deciding between two colleges that have both offered him soccer scholarships. He’s also spent time playing soccer in Spain, and this summer will play for Villarreal C.F. U19 Men's North American Team. The story of how Nacho went from being told to consider the chess team to living the life of an elite youth soccer player is nothing short of inspiring. It demonstrates that people with asthma can manage their disease and live a full life.

The transition for Nacho started on a basketball court in Colorado. There, he learned at a young age that he loved sports and by managing his asthma, he could participate in and enjoy them.

A few years later in Michigan, he found his love for soccer. Nacho was determined. He began to follow elite soccer players and high-profile teams.

He also played – a lot.

Nacho credits his passion for soccer as a key motivator for him to manage his asthma. He worked with his doctor to build his lung capacity, slowly working up to longer and more intense levels of activity.

A combination of closely following his asthma treatment plan and understanding his physical limits helped him build strength and stamina over time.

Nacho wasn’t just good at soccer. He was club team elite.

When he was offered the opportunity to play for a club team when his family moved to Nebraska, he was ecstatic. Of course, this would mean more intense games and more challenges in managing his asthma.

Nacho would not give up.

Nacho and his mom worked with an allergist to create a clear asthma treatment plan. Nacho knows that treating with medicine, managing his exposure to his triggers, and following a strict routine allows him to play the game he loves.

Nacho and his mom both acknowledged that his story would not be possible without access to health care coverage.

“We are both committed to continuing to advocate for equitable, affordable health care access,” the two said.

Nacho also credits the newer options of asthma medicines as a key part of his ability to manage his condition.

He says he is determined to focus on “living, not just surviving.”

When asked what he would say to a young person with asthma, Nacho said, “Don’t let asthma limit you. Talk to your family, talk to your doctor, and find a way to live your dreams. My story is proof that people with asthma can enjoy an amazing quality of life.”

In the past few years, researchers have found several possible links to health conditions and low levels of vitamin D. According to studies, most people in the U.S. have low levels of vitamin D.

With all the benefits vitamin D is thought to have, can it help your asthma? Here’s what you need to know.

What Is Asthma?

Asthma is a chronic disease that causes airways to become inflamed (swollen) and narrow, making it hard to breathe. There is no cure for asthma. People with asthma manage their disease by:

• Avoiding triggers
• Taking prescribed medicines to control and treat asthma
  
  

Common symptoms of asthma are coughing, shortness of breath, wheezing and chest tightness (or pain). Asthma may lead to a medical emergency. If symptoms do not improve after following your Asthma Action Plan, call your asthma care provider or 911 right away. If you do not have an Asthma Action Plan, ask your asthma care provider so you know what to do and when to call for help.

What Is Vitamin D?

Vitamin D is an important vitamin that helps your body absorb calcium. This is important for your bones and muscles. It also supports your nervous system and immune system. Vitamin D is often called the “sunshine vitamin.” Being out in the sun helps human skin make vitamin D. But many people do not get enough. People who do not get enough vitamin D through sunlight include:

• People with darker skin
• People who protect their skin from the sun when they are outside (clothing, shade, UV protection)
• Older adults and people who rarely go outside
• And people who live in certain locations (including much of the U.S.!)
  
  

You can also get vitamin D in the foods you eat or through supplements.

What Does Science Say About Vitamin D and Asthma?

Research shows an important relationship between low vitamin D and poor bone health. Scientists believe vitamin D may impact other areas of health.

Here is a recent analysis of multiple studies that look at the link between vitamin D and asthma:

In 2016, researchers found vitamin D is likely to reduce the risk of severe asthma attacks and health care use. But these findings were generally limited to only people with mild or moderate asthma. It also only looked at people with lower baseline vitamin D levels. Children and people with frequent severe asthma attacks were under-represented.¹

In 2023, researchers looked at more recent studies. They compared the results of 20 studies. Fifteen included 1,155 children and five trials included 1070 adults with mild to moderate asthma. They concluded that vitamin D is not likely to reduce the risk of asthma episodes or attacks or improve asthma control.²

The study did not include many people with very low vitamin D levels (below 25 nmol/L), so more research may be needed in this group.

What Does This Mean for People With Asthma?

It’s still unclear how vitamin D impacts asthma. But if your vitamin D levels are low, there are ways to build your levels back up for your general health:

• Take a vitamin D supplement
• Eat foods rich in vitamin D (examples include fortified foods, mushrooms, egg yolks, some fish, cod liver oil)
• Safe sun exposure (take care not to damage your skin or put yourself at risk of skin cancer)
  
  

Taking a vitamin D supplement is the most reliable way to keep up your vitamin D levels.

If you have asthma and low vitamin D levels, don’t rely on vitamin D supplements to help you manage your asthma. Vitamin D is NOT an asthma treatment and NEVER replaces your prescription medicine. It will not make your lungs function better or treat day-to-day asthma symptoms.

If you and your doctor decide you should take a vitamin D supplement, you must also take your prescribed asthma medicine. You should not take vitamin D with certain medicines, so talk to your doctor or pharmacist. Read package inserts to make sure there aren’t any interactions.

Is Vitamin D Safe?

Yes, vitamin D is safe in the appropriate dose for general health. The NIH gives a general guide for the recommended amounts of daily vitamin D. Ask your doctor about what amount is right for you and your health.

Medical Review: May 2023 by Neeta Ogden, MD

References
1. Martineau AR, Cates CJ, Urashima M, Jensen M, Griffiths AP, Nurmatov U, Sheikh A, Griffiths CJ. Vitamin D for the management of asthma. Cochrane Database of Systematic Reviews 2016, Issue 9. Art. No.: CD011511. DOI: 10.1002/14651858.CD011511.pub2. Accessed 08 May 2023.
2. Williamson A, Martineau AR, Sheikh A, Jolliffe D, Griffiths CJ. Vitamin D for the management of asthma. Cochrane Database of Systematic Reviews 2023, Issue 2. Art. No.: CD011511. DOI: 10.1002/14651858.CD011511.pub3. Accessed 08 May 2023.

Welcome to our May research update! Getting involved with research is an important way to impact asthma and allergy treatments, education, and awareness.

The Asthma and Allergy Foundation of America (AAFA) works with doctors, researchers, patients, caregivers, public health, and government agencies to conduct and support research that is important to people affected by asthma and allergies.

Here are current research opportunities you can get involved in as a person with asthma or allergies (or as a caregiver for someone with asthma and allergies):

Interviews and Focus Groups

Participants Needed for Adolescent Asthma Self-Management Study

Researchers at Texas Woman’s University want to learn more about adolescent asthma self-management. The researchers would like to understand the experiences and perspectives of adolescents living with asthma. Adolescents will have a chance to speak about their asthma control, asthma tools, and experiences. The study format will be a private interview. Interviews will take place via Zoom.

Who may qualify to participate in this study?

• Adolescents living with asthma
• 12-18 years old
• English speaker

The study participants will be given:

• $20 Amazon gift card
• Asthma resources
  
  

Participation is voluntary. You can stop the sessions at any time. There is a potential risk for loss of confidentiality in all email downloading, electronic meetings, and internet transactions. If you have further questions about the study, please call Elif Isik (PhD, RN) at (713) 794-2109 or email her at eisik@twu.edu.

LEARN MORE

Latest Asthma and Allergy Research News

AAFA Testifies Before FDA on the Importance of Expanding Epinephrine Options
AAFA’s Chief Mission Officer, Melanie Carver, recently testified before the Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC). The PADAC is currently reviewing a new drug application submitted by ARS Pharmaceuticals Inc., for epinephrine nasal spray. In her testimony, Carver shared data from AAFA’s 2019 My Life with Food Allergy Report to highlight why people with allergies need other epinephrine options, like a nasal spray. The report showed that around 90% of the parents surveyed said their children had experienced at least one severe allergic reaction. Of these parents, nearly three out of four said their child did not get epinephrine to treat the severe allergic reaction, and 42% opted to use an antihistamine instead (which is less likely to reverse the life-threatening symptoms of anaphylaxis). One in 10 (12%) stated that fear of the injection was a reason for not using epinephrine. After deliberation, the advisory committee voted to recommend the approval of neffy®, nasal epinephrine by ARS Pharmaceuticals, Inc., for both adults and children. The FDA is expected to make a decision on approval later this year.

EPA Releases Report Showing Health Impacts of Climate Change on Children in the United States
Climate change is a threat to public health, and children are at higher risk for its negative impacts. A new report from the U.S. Environmental Protection Agency (EPA) shows some of the ways children are especially vulnerable to a variety of health effects from climate change. The study found that climate change is expected to increase the incidence of asthma in children. Specifically, climate-driven changes in air quality are expected to increase asthma cases between 4% and 11% annually.  The study also looked at the health effects of increased pollen. Increases in oak, birch, and grass pollen are projected to increase children’s asthma-related emergency department visits from 17%-30% each year. The findings of the report serve as an important new resource to address the climate crisis, advance environmental justice, and improve the health and lives of children.

New Study Shows Positive Results for Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
About 2% of children in the U.S. have peanut allergy, and this number has increased during the past 20 years. There are currently no FDA-approved treatments for peanut allergy in children younger than 4 years old, but research shows that treatment at a young age may be more effective than in older populations. In this study, researchers aimed to see if using a peanut patch could help treat peanut allergy in children between the ages of 1 and 3. This type of treatment has already been proven to be safe and effective in children 4 to 11 years old. Researchers measured the effectiveness of the treatment by testing how much peanut protein it took to cause an allergic reaction after 12 months of using the patch. They found that 67% of the children who received the peanut patch showed improvement compared to only 33.5% who did not receive the peanut patch. Serious side effects were found in both groups, so more research is needed to understand the treatment’s safety. However, these results are promising in the search for new treatments for young children with peanut allergy.

Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)
Aquestive Therapeutics announced that the FDA has conditionally accepted the name Anaphylm™ (pronounced “ana-PHYLM”) for their new product. Anaphylm is a new form of epinephrine that is put under the tongue. The name was chosen after getting feedback from patients and branding experts. The company also did a study to make sure doctors and nurses could understand the name and prescribe the product safely. The product is still in development but is designed to treat severe allergic reactions, including anaphylaxis. Final approval of the Anaphylm name will depend on FDA approval of the product.

FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
The FDA has approved the first vaccine for respiratory syncytial virus (RSV) for use in the United States. RSV is a highly contagious virus that causes infections of the lungs and breathing passages in individuals of all age groups. In older adults, RSV is a common cause of lower respiratory tract disease (LRTD), which affects the lungs and can cause life-threatening pneumonia and bronchiolitis (swelling of the small airway passages in the lungs). The new RSV vaccine is called Arexvy and is approved to prevent LRTD caused by RSV in people 60 and older. Arexvy was approved by the FDA following a clinical study showing the safety and effectiveness of the vaccine. The maker of Arexvy, GlaxoSmithKline, will continue to study the vaccine.

New Report: Health Conditions and Health Care Use Among American Indian and Alaska Native Adults by Tribal Land Residential Status: United States, 2019–2021
A new report from the Centers for Disease Control and Prevention (CDC) looks at health conditions and health care use among American Indian and Alaska Native adults by tribal land residential status. The American Indian (AI) and Alaska Native (AN) people have long experienced health disparities when compared to other American people. However, data on asthma conditions for AI/AN communities are usually limited. The new report shows that 11.1% of AI/AN adults living on tribal lands and 13.0% of AI/AN adults living off tribal lands have asthma.  These estimates are about 1.5x higher than the national asthma prevalence rates for adults (8.0%). This research highlights the value of collecting data that look more closely at differences by contextual factors, like area of residence. More research is needed to look at access to and use of health care by the AI/AN population at a more detailed level.

National Eosinophil Awareness Week is May 14-20, 2023. The purpose of this week is to raise awareness and educate about eosinophil-associated diseases.

One of these diseases is eosinophilic esophagitis (EoE). EoE is a chronic inflammatory condition of the esophagus (the tube that connects the mouth to the stomach). EoE happens when a large number of white blood cells called eosinophils [EE-oh-sin-oh-FILLS] collect and cause damage in the lining of the esophagus. It is often an immune response to food, but in some cases, environmental pollen can also trigger EoE. The inflammation caused by the eosinophils damages the surrounding tissue. Left untreated, EoE may cause the esophagus to narrow, contributing to food impactions (food getting stuck in the throat).

To raise awareness during National Eosinophil Awareness Week, the Asthma and Allergy Foundation of America (AAFA) has released two EoE resources:

• Life with EoE: The Patient Experience and Opportunities to Improve Care in the U.S. report
• Your Guide to Managing Eosinophilic Esophagitis (EoE)
  
  

Life with EoE: The Patient Experience and Opportunities to Improve Care in the U.S. Report

AAFA and the American Partnership for Eosinophilic Disorders (APFED) published a new report called Life with EoE: The Patient Experience and Opportunities to Improve Care in the U.S. The report highlights the current state of EoE care in the United States. This includes challenges and barriers to timely diagnosis, quality medical care, effective treatments, and access to resources for EoE. These challenges also present opportunities to address the unmet needs and improve future care for people living with EoE in the United States.

The new report is the result of a multi-component needs assessment of EoE. Data were collected through social listening of peer-to-peer discussions, one-on-one interviews with EoE patients and caregivers, a survey of EoE patients and caregivers, and a survey of health care providers who treat people with EoE. This study aimed to:

• Understand the current state of EoE care in the U.S.
• Understand the patient journey for EoE
• Understand health care providers’ awareness of and practice around EoE
• Identify unmet needs for EoE patients and family members
• Identify unmet needs for health care providers caring for EoE patients
  
  

Key findings from the report include:

• Many patients experience delays in diagnosis for EoE, leading to delayed symptom relief, clinical care, and treatment. Challenges to timely and accurate diagnosis include having to see multiple doctors before finding one knowledgeable in EoE, experiencing initial misdiagnoses, not recognizing symptoms as indicative of an underlying condition, and doctors dismissing symptoms.
  
  
• Signs and symptoms of EoE are not well-understood and mimic many other diseases, further delaying EoE diagnosis. Lack of awareness of EoE symptoms among patients/caregivers and HCPs is a key driver of delayed diagnosis.
  
  
• Multidisciplinary care teams are common for EoE management. Two thirds of patients/caregivers reported seeing more than one type of doctor for EoE, and HCPs reported high levels of collaboration with other doctors.
  
  
• Limited options in FDA-approved treatments for EoE lead to frustration and challenges. Elimination diets, PPI, and topical steroids were commonly-used treatments for EoE, but patients/caregivers and HCPs reported concerns and challenges with all treatments.
• Adherence to treatment plans—particularly dietary therapies—poses the greatest challenge in managing EoE.
  
  
• EoE has a significant impact on social and emotional well-being, with a majority of health care providers saying their patients with EoE typically experience anxiety and/or depression more than once a year.
  
  
• Patients/caregivers and HCPs acknowledge a greater need for support and resources for EoE, including comprehensive resources that cover a broad range of experiences.
  
  

AAFA and APFED hope this new report will serve to highlight the EoE patient voice and inspire action from key EoE stakeholders, such as health care providers, payers, pharmaceutical companies, legislators, and others to address unmet needs for EoE patients and caregivers.

Download, print, and share the report

Your Guide to Managing Eosinophilic Esophagitis (EoE)

EoE can be a complex condition to manage. AAFA and our food allergy division, Kids with Food Allergies (KFA), have created a guide called Your Guide to Managing Eosinophilic Esophagitis (EoE) to help you understand the basics of EoE and how to manage it. This guide covers:

• What EoE is
• Signs and symptoms in infants, children, and adults
• How EoE is diagnosed
• How EoE is treated
• Ways to manage the impact of EoE on your quality of life
• How to find support

Download, print, and share

The Life with EoE report and Your Guide to Managing Eosinophilic Esophagitis (EoE) were developed independently by the Asthma and Allergy Foundation of America and made possible by support from Sanofi and Regeneron.

The Asthma and Allergy Foundation of America (AAFA) is a partner organization in the National Institutes of Health's Breathe Better Network. We work together to raise awareness about asthma and lung health. We help people learn about proven medical guidelines and interventions.

We recently hosted a chat with the American Academy of Allergy, Asthma & Immunology (AAAAI) – which is also a member of the Breathe Better Network - and David Stukus, MD, a member of AAFA’s Medical Scientific Council, to address common misunderstandings about asthma and allergies.

Here are some highlights from the chat:

Q: Why is my doctor recommending a steroid medicine for my asthma instead of albuterol? Aren’t steroids more dangerous?

Inhaled steroids are safe and effective for controlling asthma inflammation. They are one of three types of inhaled asthma medicines. They are safer than oral corticosteroids (such as prednisone).

A1: There are three types of inhaled asthma medicines: https://t.co/xNoa1Gmt69 #AllergyReady
1⃣ Quick-relief medicines work quickly to relieve sudden symptoms. You take them as needed and at the first sign of symptoms. #AllergyReady https://t.co/TpPLwi9CFx pic.twitter.com/kbdSH19z3y

— AAFA National (@AAFANational) May 10, 2023

Inhaled steroids are much safer than oral steroids for treating #asthma but still need to be used in proper doses to limit side effects.

I coauthored a review on this & other common #allergy medications for @JACIInPractice
Check it out: https://t.co/elQTVz8e5i#AllergyReady https://t.co/JZTitzo2By pic.twitter.com/m0MWC1jTty

— Dr. Dave Stukus (@AllergyKidsDoc) May 10, 2023

You can find additional information on inhaled corticosteroids in this fact sheet: https://t.co/eiM1uz4njh #AllergyReady #AsthmaAwareness

— Breathe Better (@BreatheBetter) May 11, 2023

Q: Why do I need a valved holding chamber? Aren't they only for kids?

Everyone who uses a metered dose inhaler should use a valved holding chamber. It creates space for the liquid medicine to turn into an aerosol when it comes out of the inhaler. This helps more medicine get into your lungs where it belongs.

A2: Using a valved holding chamber or spacer with MDI inhalers can improve how much medicine gets into your lungs. The chamber attaches to an MDI and turns the medicine into smaller particles that are easier to inhale. https://t.co/zdUMQ6l4qA #AllergyReady https://t.co/rjuCnrM01c pic.twitter.com/WgwsluDkcJ

— AAFA National (@AAFANational) May 10, 2023

Q: Why is BENADRYL® not the best option to treat seasonal allergies?

Diphenhydramine (BENADRYL®) is not recommended for treating allergies because of its short-term action to manage symptoms and several known negative side effects. It can cause drowsiness, sedation, and fatigue. It can impair alertness, concentration, multitasking, and memory. This antihistamine can impair important functions like learning in children and operating machinery and cars in adults. New antihistamines, such as cetirizine (ZYRTEC®) and loratadine (Claritin®), work longer and are safer.

1st generation antihistamines are outdated, associated with many side effects and not nearly as effective as 2nd generation (zyrtec, claritin, allegra).

Don't take my word for it. GREAT information here: https://t.co/sKUWipqqAu#AllergyReady https://t.co/VqH1NIaZ0a

— Dr. Dave Stukus (@AllergyKidsDoc) May 10, 2023

A3 We created a reference guide of medications that are used to treat allergies & asthma. All are prescription meds. This guide includes: FDA approved use for the medication, dosing, generic and brand names and links to product websites. #AllergyReadyhttps://t.co/WcGSZW6vCw

— AAAAI (@AAAAI_org) May 10, 2023

Q: I’ve heard about “natural” ways to treat my allergies. Do any of these work?

Reducing your exposure to allergens in your home can help improve allergy symptoms. You can also use a nasal rinse and artificial tears (eye drops) to help manage symptoms. But honey won’t help.

My favorite natural treatment: Clarify exactly what is causing allergies and adopt specific avoidance measures to reduce exposure (if/when possible)
Also:
Nasal saline/irrigation is AMAZING!
Artificial tears for eyes

🍯Commonly marketed but not actually helpful#AllergyReady https://t.co/dB6S4SjeQU

— Dr. Dave Stukus (@AllergyKidsDoc) May 10, 2023

A4: Reduce exposure to allergens to improve allergy symptoms.
✅ Check pollen count
✅ Close windows during peak pollen
✅ Remove shoes to enter home
✅ Wipe down pets
✅ Don't dry laundry outdoors
✅ Cover hair, nose, mouth, eyes when outside
✅ Shower before bed#AllergyReady https://t.co/kvidVLjEWm pic.twitter.com/dac1VbtyNu

— AAFA National (@AAFANational) May 10, 2023

Q: What’s the difference between a food allergy and a food intolerance?

Food allergies are caused by reaction of your immune system. Food intolerances are when your digestive system (gut) has a hard time digesting food.

A6: There are many misconceptions about food allergies, intolerances, and sensitivities. @AllergyKidsDoc talks about the differences and getting the right diagnosis. Learn more: https://t.co/nAvMunTtfZ @AllergyKidsDoc #AllergyReadyhttps://t.co/ieGuJXNAQW https://t.co/c5cMFqZAr7

— KidsWithFoodAllergies (@kfatweets) May 10, 2023

Watch on YouTube

Check out #AllergyReady on Twitter to read the rest of the chat!

Do you know the truth behind these common asthma myths? Read on to test your knowledge about asthma.

Myth: You can outgrow asthma.

Fact: Some people may be diagnosed with asthma as a child and then find their symptoms improve when they become an adult. Or they may develop asthma as an adult and then their asthma seems to go into remission. While asthma can naturally improve over time, people with asthma should stay aware that symptoms can return. It can be controlled. It can improve. Your symptoms may get better but may reappear at any time.

Myth: If you don’t wheeze, you don’t have asthma.

Fact: Wheezing is a common symptom of asthma. But it’s not the only one. And not everyone with asthma has the same symptoms. You may only have one symptom, or you may have many symptoms. So if you don’t wheeze, you can still have asthma.

Common signs and symptoms of asthma include:

• Shortness of breath
• Cough
• Chest tightness or pain
• Wheeze (a whistling sound when you breathe)
• Waking at night due to asthma symptoms
• A drop in your peak flow meter reading (if you use one)
  
  

Watch on YouTube

Myth: Face masks make asthma worse.

Fact: Face masks can actually benefit people with asthma. They can reduce your exposure to asthma triggers, like pollen, dust, and strong scents. They can also reduce your chance of catching a respiratory illness, such as the flu, RSV, and COVID-19.

Watch on YouTube

Myth: Asthma isn’t a serious condition.

Fact: Asthma is serious. About 10 people die from asthma each day. It is one of the top reasons people miss work and school. Indigenous people have the highest asthma rates, deaths, and hospital stays. Asthma has a major impact on a person’s emotional, social, financial, and physical health.

Myth: People with asthma can’t live a “normal” life.

Fact: People with asthma absolutely can live a full, active life. If your asthma is well-controlled, it should not hold you back from doing every day activities and exercising. In fact, many Olympic and professional athletes have asthma. If asthma is affecting your quality of life, talk with your doctor about your treatment plan to find a way to help you get your asthma under control.

Recall Notice - SD Biosensor, Inc. Requests Discontinuation of Use and Disposal of Specific Pilot™ COVID-19 At-Home Tests in the United States Due to Microbial Contamination in the Liquid Buffer Solution

For Immediate Release

May 4, 2023

Contact Information

Roche Customer Support Center
1-866-987-6243

Company Announcement

SEOUL, South Korea, May 4, 2023 /PRNewswire/ -- SD Biosensor, Inc. today is requesting that consumers stop using and dispose of specific Pilot COVID-19 At-Home Tests in the United States because potentially harmful bacteria were found in the tube with liquid inside (pouch 2 of the kits).

The affected tests can be identified by the lot number on the outer packaging and should be appropriately discarded. Dispose of the entire test kit in the household trash. Do not pour the liquid down the drain.

Direct exposure to the liquid in the tube through misuse or spillage could potentially lead to serious illness.

To date, no such illness has been reported. If the liquid in the tube contacts your skin and eyes, flush with large amounts of water and if irritation persists, seek medical attention.

The affected test kits were distributed by Roche Diagnostics to distributors and retailers in the U.S. Product images, lot information and follow-up actions are available at go.roche.com/pilottestExternal Link Disclaimer or by contacting the Roche Customer Support Center at 1-866-987-6243 and selecting option 1.

Lot Numbers

• 53K38N1T1
• 53K38N2T1
• 53K38N3T1
• 53K38N4T1
• 53K38N5T1
• 53K38P1T1
• 53K38P2T1
• 53K38P3T1
• 53K41T5T1
• 53K41X1T1
• 53K41X2T1
• 53K41X3T1
• 53K4211T1
• 53K4212T1
• 53K4213T1
• 53K4221T1
• 53K4222T1
• 53K4223T1
• 53K4224T1
• 53K4225T1
• 53K4231T1
• 53K4232T1
• 53K4233T1
• 53K4261T1
• 53K4262T1
• 53K4271T1
• 53K4272T1
• 53K4273T1
• 53K4274T1
• 53K4291T1
• 53K4292T1
• 53K42A1T1
• 53K42A2T1
• 53K42A3T1
• 53K42E1T1
• 53K42G1T1
• 53K42G2T1
• 53K42H1T1
• 53K42H2T1
• 53K42L1T1
• 53K42L2T1
• 53K4361AC
• 53K4362AC
• 53K4392AC

The Pilot COVID-19 At-Home Test is an over-the-counter rapid antigen test and uses a nasal swab sample that can be self-collected and self-tested by individuals ages 14 years and older, and by an adult for children ages 2 to 13 years old.

Individuals performing the self-test may run the risk of direct contact with the contaminated liquid in the tube. The liquid is contained in an individual, ready-to-use, pre-filled and sealed tube, but a user may inadvertently come in direct contact with the contaminated liquid during opening the tube or handling of the open tube or while performing the test.

This request to discontinue use and dispose of the affected tests is currently isolated to specific lots of the Pilot COVID-19 At-Home Test, distributed by Roche Diagnostics, exclusively in the U.S. Roche-branded rapid antigen tests authorized in markets outside of the U.S. are unaffected.

You may report adverse events such as unexpected side effects or injury or product quality problems to the U.S. Food and Drug Administration's (FDA's) MedWatch Adverse Event Reporting program in the following ways:

Online: Complete and submit a report on this FDA webpage.
Standard mail or fax: Download this form or call 1-800-332-1088 to request a form. Then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.
For more information, please view MedWatch Online Voluntary Reporting Form (fda.gov). This action is being taken with the knowledge of the FDA.

References

This product has not been FDA cleared or approved, but has been authorized by the FDA under an Emergency Use Authorization. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is authorized only for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in-vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

SOURCE SD Biosensor

Advocating for people with asthma and allergies is a great way to spread awareness during National Asthma and Allergy Awareness Month. We invite you to join us for Local Advocacy Action Day!

On May 9, we ask you to help us tell your state legislators what people with asthma and allergies need to live full, healthy lives. More than 100 million Americans have asthma and/or allergies. And some people may have one or both of these conditions for which there is no cure.

• About 25.5 million in the U.S. have asthma
• About 20.3 million in the U.S. have food allergies
• About 80.3 million in the U.S. have seasonal allergies
  
  

These numbers paint a picture of how many people in the U.S. are managing asthma and allergies. But they don’t show the overall impact these diseases have on people and communities.

We need lawmakers to consider our health in all policies, not just health care policies. We need local community leaders to take action too. People with asthma and allergies in the United States need the following to live healthy and full lives:

• Affordable, accessible, quality health care
• Clean air
• Healthy homes
• Safe food
• Financial stability
• Education
  
  

One way you can take action today is by contacting your state legislators using our simple tool below. By filling out this form, you will send a pre-drafted email to your state legislators to help raise awareness in your local community. You can edit this email to add your personal story and share why you advocate.

Climate change is a major threat to public health.¹ It increases both air pollution and pollen counts. Some groups are at a greater risk of feeling the effects of climate change than others, including people with chronic diseases like asthma and allergies.

May 1-5, 2023, is Air Quality Awareness Week. This week, the Environmental Protection Agency (EPA) and several other government agencies raise awareness about the importance of air quality.

During Air Quality Awareness Week, the Asthma and Allergy Foundation of America (AAFA) looks at the major impact climate change and air pollution have on people with asthma and allergies.

Climate Change and Seasonal Allergies

In AAFA’s 2023 Allergy Capitals™ report, we highlighted the dangerous cycle of climate change. As global temperatures rise, extreme weather events become worse. Weather changes – such as heat waves and droughts – can lead to stagnant air (a lack of airflow). When the air doesn’t move, pollutants react together in the heat and sun. This increases ground-level ozone.

Ground-level ozone is a major part of urban smog. More air pollution and smog cause higher levels of carbon dioxide (CO₂). This results in warmer temperatures. And the cycle continues.

Warmer temperatures along with higher levels of CO₂ make growing seasons longer. This allows plants more time to flower and produce pollen.

This climate change cycle causes longer and more intense allergy seasons. It also increases asthma and allergy triggers. This can make symptoms worse for people with seasonal pollen allergies and allergic asthma.

When looking at the connection between climate change and seasonal allergies, two factors have to be considered: botanical sexism and urban heat islands.

Botanical Sexism

Trees also play a role in climate change and seasonal allergies. Tree pollen is a common allergen. It has increased over the years more than grass or weed pollen.² “Botanical sexism” is partly to blame. This is when communities choose to plant more wind-pollinating trees than fruiting trees. (Wind-pollinating trees are sometimes called “male” trees, and fruit-bearing trees are sometimes called “female” trees.) More wind-pollinating trees can lead to higher pollen.

Urban Heat Islands

Many of the health impacts of climate change are felt more in urban areas. Warmer temperatures and extreme heat waves are made worse in urban areas due to an effect called an “urban heat island” (UHI). A UHI is a metropolitan area that has higher temperatures than its surrounding areas.

The extreme heat makes air pollution and allergic sensitivity worse. Pollution from vehicles, power plants, and industry in cities can be very high and can impact pollen production. In fact, ragweed pollen has been found to be much higher in certain cities than in surrounding rural areas.³

Reducing the Impact of Climate Change

We need to slow the cycle of climate change to improve health of people with asthma and allergies. If we don’t act, pollen counts will only get higher, temperatures will continue to rise, and urban centers will continue to see the harsh effects of climate change.

To learn more about climate change and how we can reduce its impact, read the 2023 Allergy Capitals report.

The 2023 Allergy Capitals report is an independent research project of AAFA and is made possible by a research support grant from the Consumer Healthcare Products Association.

References
1. Wuebbles, D.J., Fahey, D.W., Hibbard, K.A., et al. (2018). Fourth National Climate Assessment: Climate science special report. U.S. Global Change Research Program. https://www.globalchange.gov/nca4
2. Climate Central. (2023). Seasonal allergies: pollen and mold. https://assets.ctfassets.net/cxgxgstp8r5d/6HEq6ZLb0QpvXxScvaM7sc/ ae3024a9c4f2bcdd9b563d09b1bd07c3/ FINALSeasonal_allergies_pollen_and_mold_2023__ EN_.pdf
3. Ziska, L. H., Gebhard, D. E., Frenz, D. A., Faulkner, S., Singer, B. D., & Straka, J. G. (2003). Cities as harbingers of climate change: Common ragweed, urbanization, and public health. Journal of Allergy and Clinical Immunology, 111(2), 290–295. https://doi.org/10.1067/mai.2003.53